Wall Street analysts expect Solid Biosciences Inc (NASDAQ:SLDB) to report earnings of ($0.55) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Solid Biosciences’ earnings. The highest EPS estimate is ($0.54) and the lowest is ($0.55). The firm is expected to announce its next quarterly earnings report on Friday, November 9th.
On average, analysts expect that Solid Biosciences will report full-year earnings of ($2.21) per share for the current year, with EPS estimates ranging from ($2.26) to ($2.18). For the next fiscal year, analysts forecast that the company will report earnings of ($2.45) per share, with EPS estimates ranging from ($2.93) to ($2.07). Zacks’ EPS calculations are an average based on a survey of analysts that that provide coverage for Solid Biosciences.
Solid Biosciences (NASDAQ:SLDB) last posted its earnings results on Friday, August 10th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.01).
NASDAQ:SLDB opened at $35.50 on Friday. Solid Biosciences has a 1 year low of $6.83 and a 1 year high of $54.84. The firm has a market capitalization of $1.67 billion and a P/E ratio of -12.33.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Schwab Charles Investment Management Inc. grew its position in Solid Biosciences by 7.5% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 38,011 shares of the company’s stock worth $1,355,000 after purchasing an additional 2,658 shares during the last quarter. Partner Investment Management L.P. bought a new position in shares of Solid Biosciences during the 2nd quarter worth about $134,000. Rhumbline Advisers bought a new position in shares of Solid Biosciences during the 2nd quarter worth about $306,000. Bank of New York Mellon Corp lifted its holdings in shares of Solid Biosciences by 58.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 31,889 shares of the company’s stock worth $1,137,000 after acquiring an additional 11,726 shares during the period. Finally, California State Teachers Retirement System bought a new position in shares of Solid Biosciences during the 1st quarter worth about $104,000. Institutional investors own 60.13% of the company’s stock.
Solid Biosciences Company Profile
Solid Biosciences Inc engages in identifying and developing therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, a gene therapy that is in Phase I/II clinical trials to restore functional dystrophin protein expression in patients' muscles. The company's product candidates also comprise SB-001, a monoclonal antibody to reduce fibrosis and inflammation.
Featured Article: Market Capitalization in the Stock Market
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.